Role of carfilzomib in the treatment of multiple myeloma

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

(2011) J. D. Shaughnessy et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

(2011) J. Yang et al.   DRUG METABOLISM AND DISPOSITION

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Management of treatment-emergent peripheral neuropathy in multiple myeloma

(2011) P G Richardson et al.   LEUKEMIA

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

The resurgence of covalent drugs

(2011) Juswinder Singh et al.   NATURE REVIEWS DRUG DISCOVERY

Racial disparities in incidence and outcome in multiple myeloma: a population-based study

(2010) A. J. Waxman et al.   BLOOD

Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry

(2010) E. Genin et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

(2010) Michel Delforge et al.   LANCET ONCOLOGY

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

(2010) M Ri et al.   LEUKEMIA

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

(2010) Guido Cavaletti et al.   LEUKEMIA & LYMPHOMA

Characterization of bortezomib-adapted I-45 mesothelioma cells

(2010) Lidong Zhang et al.   Molecular Cancer

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

(2009) Hongjuan Dong et al.   LEUKEMIA & LYMPHOMA

Management of Complications in Multiple Myeloma

(2009) Evangelos Terpos et al.   SEMINARS IN HEMATOLOGY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

NF-??B in the pathogenesis and treatment of multiple myeloma

(2008) Zhi-Wei Li et al.   CURRENT OPINION IN HEMATOLOGY

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE